U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H23Cl2N3OS
Molecular Weight 448.4103
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of ELZASONAN

SMILES

CN1CCN(CC1)c2ccccc2/C(/[H])=C\3/C(=O)N(CCS3)c4ccc(c(c4)Cl)Cl

InChI

InChIKey=LHYMPSWMHXUWSK-STZFKDTASA-N
InChI=1S/C22H23Cl2N3OS/c1-25-8-10-26(11-9-25)20-5-3-2-4-16(20)14-21-22(28)27(12-13-29-21)17-6-7-18(23)19(24)15-17/h2-7,14-15H,8-13H2,1H3/b21-14-

HIDE SMILES / InChI

Molecular Formula C22H23Cl2N3OS
Molecular Weight 448.4103
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Elzasonan (CP 448187) is a serotonin 1B/1D receptor antagonist. Elzasonan was primarily metabolized via oxidative N‐demethylation, N‐oxidation, and aryl hydroxylation. Pfizer was developing elzasonan for the treatment of anxiety and affective disorders however development has been discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed
Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays.
2013 Jun 17
Patents

Patents

Substance Class Chemical
Created
by admin
on Sat Jun 26 08:58:43 UTC 2021
Edited
by admin
on Sat Jun 26 08:58:43 UTC 2021
Record UNII
933PJL964R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ELZASONAN
INN  
INN  
Official Name English
(2Z)-4-(3,4-DICHLORPHENYL)-2-(2-(4-METHYLPIPERAZIN-1-YL)BENZYLIDENE)THIOMORPHOLIN-3-ONE
Common Name English
3-THIOMORPHOLINONE, 4-(3,4-DICHLORPHENYL)-2-((2-(4-METHYL-1-PIPERAZINYL) PHENYL)METHYLENE)-, (2Z)-
Common Name English
ELZASONAN [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66885
Created by admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
Code System Code Type Description
EPA CompTox
361343-19-3
Created by admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
PRIMARY
FDA UNII
933PJL964R
Created by admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
PRIMARY
CAS
205683-28-9
Created by admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
NON-SPECIFIC STEREOCHEMISTRY
PUBCHEM
6914152
Created by admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
PRIMARY
MESH
C556408
Created by admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
PRIMARY
ChEMBL
CHEMBL2110932
Created by admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
PRIMARY
NCI_THESAURUS
C72755
Created by admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
PRIMARY
CAS
361343-19-3
Created by admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
PRIMARY
INN
8240
Created by admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TARGET->ANTAGONIST
SALT/SOLVATE -> PARENT
EXCRETED UNCHANGED
FECAL
EXCRETED UNCHANGED
URINE
Related Record Type Details
METABOLITE -> PARENT
FECAL
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
M6 accounted (average of six human subjects) for 5.6% (sum of M5 and M6) of the administered dose in feces
FECAL
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
sum of M5 and M6 counted for 5.6% of the administered dose in feces
FECAL
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION